Loading...Loading...Codexis, Inc. CDXS entered a purchase deal with Nestlé S.A.NSRGY Nestlé Health Science for CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI). Under the terms of the agreement, Codexis will receive up to $45 million in potential milestone payments, including a $5 million upfront payment, as well as single-digit net-sales-based royalties.Codexis will receive up to an additional $5 million if Nestlé Health Science exercises an option to purchase two additional early-stage enzymes being developed for EPI.CDX-7108 is a lipase variant specifically engineered to overcome the limitations of traditional pancreatic enzyme replacement therapy (PERT) deficiencies.

正在加载。。。正在加载。。。Codexis，Inc.CDXS与雀巢公司（NestléS.a.NSRGY NestléHealth Science）签订了CDX-7108的购买协议，CDX-7108是一种治疗外分泌性胰腺功能不全（EPI）的潜在药物。根据协议条款，Codexis将获得高达4500万美元的潜在里程碑付款，包括500万美元的预付款，以及基于销售额的单位净版税。如果雀巢健康科学公司（NestléHealth Science）选择购买另外两种为EPI开发的早期酶，Codexis将获得高达500万美元的额外资金。CDX-7108是一种脂肪酶变体，专门用于克服传统胰酶替代疗法（PERT）缺陷的局限性。

PERT is the main treatment for EPI, a debilitating condition of the gastrointestinal tract that is caused by conditions that impair pancreatic function.Stephen Dilly, CEO of Codexis, said, 'Preliminary data from the CDX-7108 Phase I study announced earlier this year support continued investigation into Phase II clinical studies.

PERT是EPI的主要治疗方法，EPI是由损害胰腺功能的疾病引起的胃肠道衰弱状态。Codexis首席执行官斯蒂芬·迪利（StephenDilly）表示，“今年早些时候公布的CDX-7108第一阶段研究的初步数据支持继续进行第二阶段临床研究的调查。

We believe that CDX-7108 could represent a meaningful advance in the standard of care for patients, and we are pleased to retain an economic interest in the program as Nestlé continues development.'Nestlé Health Science will be exclusively responsible for further advancing and marketing CDX-7108, covering all related expenses..

我们相信，CDX-7108可以代表患者护理标准的一个有意义的进步，随着雀巢的不断发展，我们很高兴对该计划保持经济利益。”雀巢健康科学将专门负责进一步推进和营销CDX-7108，涵盖所有相关费用。。

Price Action: CDXS shares are trading higher by 4.52% at $3.47 on the last check Wednesday. Disclaimer: This content was partially produced with the help of AI tools and was Reviewed And Published By Benzinga Editors.Loading...Loading...

价格走势：周三最后一次检查中，CDX股价上涨4.52%，至3.47美元。免责声明：此内容部分是在AI工具的帮助下制作的，并由Benzinga编辑审阅和发布。正在加载。。。正在加载。。。